Tulane University School of Medicine Uses SOPHiA GENETICS to Advance Research of Blood Cancers

News provided by

Aug 08, 2023, 06:55 ET

The School of Medicine will use the SOPHiA DDM™ Platform to expand its hematologic testing program for blood cancers

BOSTON and ROLLE, Switzerland, Aug. 8, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that the Tulane University School of Medicine in New Orleans, Louisiana is live on SOPHiA GENETICS technology. The 15^th oldest medical school in the United States, Tulane University School of Medicine has a longstanding history of medical research and education and will leverage the SOPHiA DDM™ Platform to help scale its hematologic (blood) testing program to advance blood cancer research.

Blood cancers account for nearly 10 percent of new cancer cases in the U.S. each year¹. While there are three main types of blood cancer – leukemia, lymphoma, and myeloma – there are over 100 different blood cancers that are now recognized². To help identify key biomarkers and aid in stratification, labs are relying on next-generation sequencing (NGS), which can produce a vast dataset. The SOPHiA DDM™ Platform will enable the Tulane University School of Medicine to quickly sort and analyze NGS data so that researchers can share data-based recommendations with clinical researchers, which is important as these malignancies can be fast-moving.

"When the time came to upgrade our sequencing platform, the SOPHiA DDM™ Platform provided a comprehensive heme panel sequencing solution. SOPHiA GENETICS offered a chance to rapidly introduce the new solutions to our service menu, and I am hopeful that this integration of SOPHiA GENETICS technology to our workflow will be the new start of our continuous efforts to improve the academic center-based genetic/genomic diagnostic services from our Louisiana communities to many more areas." said Yuwen Li, MD, PhD, Director of Molecular Genetics Diagnostic Laboratory , Tulane University School of Medicine.

The SOPHiA DDM™ Platform will also enable Tulane University School of Medicine to retain custody of its samples and data. Each test performed can be stored in the SOPHiA DDM™ Platform, which is a cloud-based platform powered by Artificial Intelligence (AI) with patented technologies. Having the ability to synthesize NGS data in-house will help Tulane University School of Medicine build its expertise and facilitate faster data turnaround from researcher to clinical researcher, helping to positively impact disease assessment.

"At SOPHiA GENETICS we believe in the power of data-driven medicine and its ability to change the face of healthcare," said Ken Freedman, Chief Revenue Officer, SOPHiA GENETICS. "With the adoption of the SOPHiA GENETICS Platform, we are confident that Tulane University School of Medicine will be able to scale its program, further research of blood cancers, and efficiently increase the use of precision medicine."

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on Twitter, LinkedIn, Facebook, and Instagram.

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

¹ https://www.lls.org/facts-and-statistics/facts-and-statistics-overview

^² https://www.yalemedicine.org/conditions/blood-cancers#:~:text=%E2%80%9CWith%20over%20100%20different%20types,Huntington.

SOURCE SOPHiA GENETICS